Skip to content

Nicolas D. Iadarola

3 papers in the library · 322 citations · publishing 2015-2017

Papers

Sort Most recent Most cited

The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder

Journal of Psychopharmacology October 17, 2017 Mark J. Niciu, Nicolas D. Iadarola, Dipavo Banerjee et al. 23 citations

BACKGROUND: This study sought to reproduce, in a larger sample, previous findings of a correlation between smaller raw 3-Tesla (3T) hippocampal volumes and improved antidepressant efficacy of ketamine in individuals with major depressive disorder (MDD). A secondary analysis stratified subjects according to functional BDNF rs6265 (val66met) genotype. METHODS: Unmedicated subjects with...

Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder

Current Neuropharmacology March 25, 2016 Brittany A. Jaso, Mark J. Niciu, Nicolas D. Iadarola et al. 97 citations

Current pharmacotherapies for major depressive disorder (MDD) have a distinct lag of onset that can prolong distress and impairment for patients, and realworld effectiveness trials further suggest that antidepressant efficacy is limited in many patients. All currently approved antidepressant medications for MDD act primarily through monoaminergic mechanisms, e.g., receptor/reuptake agonists or...

DOI: 10.2174/1570159x14666160321123221 (opens in new tab) Full text (opens in new tab) Nmda receptor Antidepressant Pharmacology Metabotropic glutamate receptor +3

Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review

Therapeutic Advances in Chronic Disease April 13, 2015 Nicolas D. Iadarola, Mark J. Niciu, Erica M. Richards et al. 202 citations

Current pharmacotherapies for major depressive disorder (MDD) and bipolar depression (BDep) have a distinct lag of onset that can generate great distress and impairment in patients. Furthermore, as demonstrated by several real-world effectiveness trials, their efficacy is limited. All approved antidepressant medications for MDD primarily act through monoaminergic mechanisms, agonists or...

DOI: 10.1177/2040622315579059 (opens in new tab) Ketamine Depression economics Perspective graphical Receptor +2